Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report issued on Sunday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Price Performance

SENS stock opened at $0.31 on Friday. The company’s 50-day moving average price is $0.34 and its two-hundred day moving average price is $0.39. The firm has a market cap of $183.72 million, a P/E ratio of -2.32 and a beta of 0.79. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a 12 month low of $0.28 and a 12 month high of $0.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in Senseonics in the first quarter valued at about $91,000. GSA Capital Partners LLP acquired a new stake in shares of Senseonics during the third quarter valued at about $117,000. Virtu Financial LLC bought a new stake in shares of Senseonics during the first quarter worth about $162,000. Finally, Symmetry Partners LLC acquired a new position in shares of Senseonics in the third quarter valued at approximately $164,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.